<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Delcath Systems Inc — News on 6ix</title>
<link>https://6ix.com/company/delcath-systems-inc</link>
<description>Latest news and press releases for Delcath Systems Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 23 Apr 2026 12:30:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/delcath-systems-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68355c4d78dffbe2df0ec421.webp</url>
<title>Delcath Systems Inc</title>
<link>https://6ix.com/company/delcath-systems-inc</link>
</image>
<item>
<title>Delcath Systems to Host First Quarter 2026 Earnings Call</title>
<link>https://6ix.com/company/delcath-systems-inc/news/delcath-systems-to-host-first-quarter-2026-earnings-call</link>
<guid isPermaLink="true">https://6ix.com/company/delcath-systems-inc/news/delcath-systems-to-host-first-quarter-2026-earnings-call</guid>
<pubDate>Thu, 23 Apr 2026 12:30:00 GMT</pubDate>
<description>QUEENSBURY, N.Y., April 23, 2026--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on May 7, 2026, at 8:30 AM Eastern Time to discuss results for its first quarter ended March 31, 2026.</description>
</item>
<item>
<title>Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN Clinical Practice Guidelines for Uveal Melanoma</title>
<link>https://6ix.com/company/delcath-systems-inc/news/delcath-systems-inc-announces-inclusion-of-chemosat-hepatic-delivery-system-for-melphalan-as-a-recommended-liver-directed-regional-therapy-option-in-the-esmo-euracan-clinical-practice-guidelines-for-uveal-melanoma</link>
<guid isPermaLink="true">https://6ix.com/company/delcath-systems-inc/news/delcath-systems-inc-announces-inclusion-of-chemosat-hepatic-delivery-system-for-melphalan-as-a-recommended-liver-directed-regional-therapy-option-in-the-esmo-euracan-clinical-practice-guidelines-for-uveal-melanoma</guid>
<pubDate>Mon, 06 Apr 2026 04:00:00 GMT</pubDate>
<description>QUEENSBURY, N.Y.--(BUSINESS WIRE)-- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on liver-directed cancer therapies,</description>
</item>
<item>
<title>Delcath Systems to Participate at the Society of Interventional Radiology 2026 Meeting</title>
<link>https://6ix.com/company/delcath-systems-inc/news/delcath-systems-to-participate-at-the-society-of-interventional-radiology-2026-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/delcath-systems-inc/news/delcath-systems-to-participate-at-the-society-of-interventional-radiology-2026-meeting</guid>
<pubDate>Wed, 01 Apr 2026 12:30:00 GMT</pubDate>
<description>QUEENSBURY, N.Y., April 01, 2026--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will attend the Society of Interventional Radiology (SIR) 2026 Annual Scientific Meeting, taking place April 11–15, 2026, in Toronto, Canada.</description>
</item>
<item>
<title>Delcath Systems Announces Publication of CHOPIN Clinical Trial Results in The Lancet Oncology</title>
<link>https://6ix.com/company/delcath-systems-inc/news/delcath-systems-announces-publication-of-chopin-clinical-trial-results-in-the-lancet-oncology</link>
<guid isPermaLink="true">https://6ix.com/company/delcath-systems-inc/news/delcath-systems-announces-publication-of-chopin-clinical-trial-results-in-the-lancet-oncology</guid>
<pubDate>Tue, 03 Mar 2026 05:00:00 GMT</pubDate>
<description>Publication Highlights Promise of Combined Percutaneous Hepatic Perfusion and Immunotherapy in Metastatic Uveal Melanoma QUEENSBURY, N.Y.--(BUSINESS WIRE)--</description>
</item>
<item>
<title>Delcath Systems Reports Fourth Quarter and Full Year 2025 Results</title>
<link>https://6ix.com/company/delcath-systems-inc/news/delcath-systems-reports-fourth-quarter-and-full-year-2025-results</link>
<guid isPermaLink="true">https://6ix.com/company/delcath-systems-inc/news/delcath-systems-reports-fourth-quarter-and-full-year-2025-results</guid>
<pubDate>Thu, 26 Feb 2026 13:00:00 GMT</pubDate>
<description>QUEENSBURY, N.Y., February 26, 2026--Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported financial results and business highlights for the fourth quarter and full year-ended December 31, 2025.</description>
</item>
<item>
<title>Delcath Systems to Host Fourth Quarter and Full Year 2025 Earnings Call</title>
<link>https://6ix.com/company/delcath-systems-inc/news/delcath-systems-host-fourth-quarter-130000755</link>
<guid isPermaLink="true">https://6ix.com/company/delcath-systems-inc/news/delcath-systems-host-fourth-quarter-130000755</guid>
<pubDate>Thu, 12 Feb 2026 13:00:00 GMT</pubDate>
<description>QUEENSBURY, N.Y., February 12, 2026--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on February 26, 2026, at 8:30 AM Eastern Time to discuss results for its fourth quarter and full year ended December 31, 2025.</description>
</item>
<item>
<title>Delcath Systems to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference</title>
<link>https://6ix.com/company/delcath-systems-inc/news/delcath-systems-participate-btig-13th-130500042</link>
<guid isPermaLink="true">https://6ix.com/company/delcath-systems-inc/news/delcath-systems-participate-btig-13th-130500042</guid>
<pubDate>Tue, 27 Jan 2026 13:05:00 GMT</pubDate>
<description>QUEENSBURY, N.Y., January 27, 2026--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference at the Cliff Lodge in Snowbird, Utah.</description>
</item>
<item>
<title>Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/delcath-systems-inc/news/delcath-systems-inc-announces-inducement-210100854</link>
<guid isPermaLink="true">https://6ix.com/company/delcath-systems-inc/news/delcath-systems-inc-announces-inducement-210100854</guid>
<pubDate>Wed, 21 Jan 2026 21:01:00 GMT</pubDate>
<description>QUEENSBURY, N.Y., January 21, 2026--Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company’s Compensation Committee, as material inducements to four individuals whose employment commenced in either November 2025 or December 2025.</description>
</item>
<item>
<title>Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/delcath-systems-inc/news/delcath-systems-announces-preliminary-fourth-130500680</link>
<guid isPermaLink="true">https://6ix.com/company/delcath-systems-inc/news/delcath-systems-announces-preliminary-fourth-130500680</guid>
<pubDate>Fri, 09 Jan 2026 13:05:00 GMT</pubDate>
<description>QUEENSBURY, N.Y., January 09, 2026--Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced preliminary financial results and business updates for the fourth quarter and year-ended December 31, 2025.</description>
</item>
<item>
<title>Delcath Systems Announces Publication of Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma</title>
<link>https://6ix.com/company/delcath-systems-inc/news/delcath-systems-announces-publication-subgroup-130000958</link>
<guid isPermaLink="true">https://6ix.com/company/delcath-systems-inc/news/delcath-systems-announces-publication-subgroup-130000958</guid>
<pubDate>Wed, 31 Dec 2025 13:00:00 GMT</pubDate>
<description>QUEENSBURY, N.Y., December 31, 2025--Delcath Systems, Inc. (Nasdaq: DCTH), ("Delcath" or the "Company") an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of results from subgroup analyses of the phase 3 FOCUS study. The publication, titled "Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma" was published in the Journal of Cance</description>
</item>
<item>
<title>Delcath Systems Announces Publication of 10-Year Single-Center Experience with Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma</title>
<link>https://6ix.com/company/delcath-systems-inc/news/delcath-systems-announces-publication-10-210100714</link>
<guid isPermaLink="true">https://6ix.com/company/delcath-systems-inc/news/delcath-systems-announces-publication-10-210100714</guid>
<pubDate>Wed, 03 Dec 2025 21:01:00 GMT</pubDate>
<description>QUEENSBURY, N.Y., December 03, 2025--Delcath Systems, Inc. (Nasdaq: DCTH), ("Delcath" or the "Company") an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of a retrospective study by leading interventional radiologists and oncologists from Asklepios Hospital Barmbek in Hamburg, Germany. The study, titled "Survival Outcome After Percutaneous Hepatic Perfusion with High-Dose Melphalan for Liver-Dominant Metastatic Uv</description>
</item>
<item>
<title>Delcath Systems Board of Directors Authorizes $25 Million Share Repurchase Program</title>
<link>https://6ix.com/company/delcath-systems-inc/news/delcath-systems-board-directors-authorizes-210100352</link>
<guid isPermaLink="true">https://6ix.com/company/delcath-systems-inc/news/delcath-systems-board-directors-authorizes-210100352</guid>
<pubDate>Thu, 20 Nov 2025 21:01:00 GMT</pubDate>
<description>QUEENSBURY, N.Y., November 20, 2025--Delcath Systems, Inc. (Nasdaq: DCTH), ("Delcath") an interventional oncology company focused on the treatment of primary and metastatic cancers to the liver, today announced that its Board of Directors has authorized a share repurchase program under which Delcath may repurchase up to $25 million of its outstanding shares of common stock from time to time, subject to market conditions. The repurchase program does not have an expiration date.</description>
</item>
<item>
<title>Delcath Systems Announces Publication of Expert Narrative Review on Percutaneous Hepatic Perfusion for Liver Metastases from Uveal Melanoma</title>
<link>https://6ix.com/company/delcath-systems-inc/news/delcath-systems-announces-publication-expert-130000004</link>
<guid isPermaLink="true">https://6ix.com/company/delcath-systems-inc/news/delcath-systems-announces-publication-expert-130000004</guid>
<pubDate>Tue, 18 Nov 2025 13:00:00 GMT</pubDate>
<description>QUEENSBURY, N.Y., November 18, 2025--Delcath Systems, Inc. (Nasdaq: DCTH), ("Delcath" or the "Company") an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of a narrative review by leading interventional radiologists and oncologists from multiple institutions. The review, titled "Treatment of Liver Metastases from Uveal Melanoma with Percutaneous Hepatic Perfusion," was published in the Journal of Vascular and Inter</description>
</item>
<item>
<title>Delcath Systems Announces Publication of Real-World Evidence Supporting Early Use of Liver-Directed Therapy with PHP in Achieving Long-Term Survival for Metastatic Uveal Melanoma Patients</title>
<link>https://6ix.com/company/delcath-systems-inc/news/delcath-systems-announces-publication-real-133000562</link>
<guid isPermaLink="true">https://6ix.com/company/delcath-systems-inc/news/delcath-systems-announces-publication-real-133000562</guid>
<pubDate>Thu, 13 Nov 2025 13:30:00 GMT</pubDate>
<description>QUEENSBURY, N.Y., November 13, 2025--Delcath Systems, Inc. (Nasdaq: DCTH), ("Delcath" or the "Company") an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of results from a retrospective analysis conducted by researchers at the University of Tubingen, Germany. The study, titled "Characterization of long-term survivors with liver metastases from uveal melanoma diagnosed between 2005 and 2021," was published in the I</description>
</item>
<item>
<title>Delcath Systems to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/delcath-systems-inc/news/delcath-systems-participate-upcoming-investor-210100702</link>
<guid isPermaLink="true">https://6ix.com/company/delcath-systems-inc/news/delcath-systems-participate-upcoming-investor-210100702</guid>
<pubDate>Thu, 06 Nov 2025 21:01:00 GMT</pubDate>
<description>QUEENSBURY, N.Y., November 06, 2025--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the following investor conferences:</description>
</item>
<item>
<title>Delcath Systems Reports Third Quarter 2025 Results and Business Highlights</title>
<link>https://6ix.com/company/delcath-systems-inc/news/delcath-systems-reports-third-quarter-130000120</link>
<guid isPermaLink="true">https://6ix.com/company/delcath-systems-inc/news/delcath-systems-reports-third-quarter-130000120</guid>
<pubDate>Tue, 04 Nov 2025 13:00:00 GMT</pubDate>
<description>QUEENSBURY, N.Y., November 04, 2025--Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the third quarter ended September 30, 2025.</description>
</item>
<item>
<title>Delcath Systems to Host Third Quarter 2025 Earnings Call</title>
<link>https://6ix.com/company/delcath-systems-inc/news/delcath-systems-host-third-quarter-123000486</link>
<guid isPermaLink="true">https://6ix.com/company/delcath-systems-inc/news/delcath-systems-host-third-quarter-123000486</guid>
<pubDate>Tue, 21 Oct 2025 12:30:00 GMT</pubDate>
<description>QUEENSBURY, N.Y., October 21, 2025--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on November 4, 2025, at 8:30 AM Eastern Time to discuss results for its third quarter ended September 30, 2025.</description>
</item>
<item>
<title>Delcath Systems Announces Preliminary Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/delcath-systems-inc/news/delcath-systems-announces-preliminary-third-201500258</link>
<guid isPermaLink="true">https://6ix.com/company/delcath-systems-inc/news/delcath-systems-announces-preliminary-third-201500258</guid>
<pubDate>Sat, 18 Oct 2025 20:15:00 GMT</pubDate>
<description>QUEENSBURY, N.Y., October 18, 2025--Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today provided preliminary revenue and financial results for the quarter ended September 30, 2025, and updated 2025 full-year revenue guidance.</description>
</item>
<item>
<title>Delcath Systems Announces Investigator-Initiated CHOPIN Clinical Trial Meets Primary Endpoint</title>
<link>https://6ix.com/company/delcath-systems-inc/news/delcath-systems-announces-investigator-initiated-201300130</link>
<guid isPermaLink="true">https://6ix.com/company/delcath-systems-inc/news/delcath-systems-announces-investigator-initiated-201300130</guid>
<pubDate>Sat, 18 Oct 2025 20:13:00 GMT</pubDate>
<description>QUEENSBURY, N.Y., October 18, 2025--Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the results of the CHOPIN randomized Phase 2 clinical trial (CHOPIN Trial) presented by Principal Investigator and Lead Author Professor Ellen Kapiteijn, MD, from Leiden University Medical Center’s Department of Medical Oncology at the 2025 European Society of Medical Oncology (ESMO) Annual Congress.</description>
</item>
<item>
<title>Delcath Systems Announces Investigator-Initiated CHOPIN Phase 2 Trial Presentation at ESMO 2025 Congress</title>
<link>https://6ix.com/company/delcath-systems-inc/news/delcath-systems-announces-investigator-initiated-200100758</link>
<guid isPermaLink="true">https://6ix.com/company/delcath-systems-inc/news/delcath-systems-announces-investigator-initiated-200100758</guid>
<pubDate>Mon, 22 Sep 2025 20:01:00 GMT</pubDate>
<description>QUEENSBURY, N.Y., September 22, 2025--Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the acceptance of an oral presentation on results from the investigator-initiated CHOPIN randomized Phase 2 trial at the 2025 European Society for Medical Oncology (ESMO) Annual Congress. Principal Investigator Ellen Kapiteijn, MD, from Leiden University Medical Center’s Department of Medical Oncology, wil</description>
</item>
</channel>
</rss>